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Gastric neuroendocrine tumors were originally thought to have a low incidence
(three percent). Since endoscopic diagnostic procedures have become clinical
routine, they are now found more frequently (relative incidence up to 41 per-
cent). In recent years, classifications have been developed that attempt to con-
sider the biological relevance of these tumors. Four types of gastric neuroen-
docrine tumor may be distinguished: Type 1 gastric neuroendocrine tumor is
most common. It is associated with chronic atrophic fundus gastritis, hypergas-
trinemia and often with pernicious anemia. Usually it is multicentric and small-
er than one cm, does not produce any symptoms and has an excellent progno-
sis. Type 2 gastric neuroendocrine tumor is second in frequency. It has no asso-
ciation with other diseases, is solitary and has no predilection for a particular
localization. It may be larger than 1 cm, produce a carcinoid syndrome or
Zollinger-Ellison syndrome and have a metastasis rate ofup to 30 percent. Type
3 gastric neuroendocrine tumor is rare and always associated with Zollinger-
Ellison syndrome and multiple endocrine neoplasia type I. It occurs as multiple
lesions in the gastric body fundus and has a lower metastatic rate than type 2
gastric neuroendocrine tumor. Type4gastric neuroendocrine tumorcorresponds
to a small-cell carcinoma.
INTRODUCTION
The incidence of gastric carcinoids, here collectively termed neuroendocrine (NE)b
tumors ofthe stomach [1], was thought to be low [2, 3], not exceeding three percent ofall
gastrointestinal neuroendocrine tumors. Recent reports, however, have challenged this fig-
ure and suggested thatthe true incidence ofgastric neuroendocrine tumors (GNET) ranges
between 11 percent and 41 percent [4-6]. These rising figures probably do not represent a
true increase in incidence, but rather indicate that the rate of occurrence was underesti-
mated in former times, because the small GNETs associated with chronic atrophic corpus
gastritis (CAG) were scarcely detected in the pre-endoscopic era.
The fact that GNETs are quite frequently encountered by the active endoscopist rais-
es the question as to theirbiology and clinical significance. During recent years, the avail-
able information has increased rapidly, culminating in detailed accounts that have led to a
better understanding ofthese lesions. As a consequence, new classifications that take their
biology and prognosis into account have been developed [1, 7-9]. Based on this work,
GNETs can be divided into four types, which we shall describe in more detail below.
CLASSIFICATION
Type 1 gastric neuroendocrine tumors
Type 1 GNET is the mostfrequent neuroendocrine tumorin the stomach, with arelative
incidence between 51 percent and 88 percent [8, 10] (Table 1). This tumor is associated with
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fundic CAG, which is usually of autoimmune nature, occurs predominantly in women and
in some 20 percent of cases is combined with pemicious anemia [10]. If only patients with
pernicious anemia are considered, GNETs may be found in five to 10 percent ofthe patients
[4, 11]. Because of the disappearance of HCl-producing cells in the fundic mucosa of the
stomach, there is sustained hypergastrinemia. Gastrin, however, is trophic for the ECL cells
ofthe fundic mucosa [12-16], leading to their numerical increase (hyperplasia) and promot-
ing their eventual clonal proliferation (tumor). Tumor development is usually multicentric
and very slow, resulting inmultiple small tumors (< 1 cm), which arerestricted to themucosa
and submucosa. Tumors that are largerthan 1 cm andinvade vessels and/orthemuscularwall
of the stomach are extremely rare. Metastasis to the regional lymph nodes or liver is there-
fore the exception [8, 10]. This implies that type 1 GNET can be controlled by endoscopic
surgery and have an excellent prognosis. Interestingly, regression ofECL-cell gastric carci-
noids has been reported in patients with pernicious anemia after elimination of hypergas-
trinemiaby antrectomy [17]. The tumors, which consist mainly ofhistamine-producing ECL
cells (with some scattered serotonin and somatostatin cells), remain non-functioning, proba-
bly because they are well differentiated and very small. The ECL cells ofthe tumors and the
cells of the precursor lesions consistently express the alpha-subunit of human chorionic
gonadotropin [18].
Type 2 gastric neuroendocrine tumors
Second in frequency to type 1 GNET are well-differentiated NE tumors thatarise spo-
radically in the gastric mucosa (Table 2). They may occur anywhere in the stomach and
are not associated with CAG or any other specific disease. Their potential to metastasize
is obviously greater than that of type 1 GNET [8, 10, 11]. If they are larger than 2 cm or
show angioinvasion and deep muscle invasion, regional lymph node metastases can be
expected in 60 percent of the cases and liver metastases in 80 percent [8]. Patients in
whom metastasis has occurred have a mean survival of about four years. Histologically,
the tumors usually show a trabecular pattern, and immunocytochemically they stain for
neuroendocrine markers [8, 10] and for biogenic amines and peptides such as serotonin,
histamine, glucagon, pancreatic polypeptide and others [19, 20]. Serotonin or histamine-
positive tumors with metastasis to the liver (about 20 to 25 percent ofall type 2 gastric NE
tumors) produce either aclassical carcinoid syndrome (due to the systemic effects of sero-
tonin) or an atypical carcinoid syndrome (due to the effects of histamine [21, 22]).
Among the sporadic GNETs, there are a few that produce gastrin. A survey ofthe lit-
erature revealed eight of these tumors that were immunocytochemically verified and
another seven tumors without detailed morphologic description (Table 3). These gastric
gastrinomas may be differentiated from the remaining GNETs, not only because of their
gastrin production, but also because of their peculiar localization. All but three of the
immunocytochemically identified gastrin-producing GNETs arose in the antropyloric
region.
Type 3 gastric neuroendocrine tumors
Type 3 GNETs are those that arise against the background ofthe inherited syndrome
of multiple endocrine neoplasia type 1 (MEN-1) presenting with the Zollinger-Ellison
syndrome (ZES) (Table 4). In this condition, the gastrinoma responsible for the ZES and
hypergastrinemia is usually found in the duodenum [33, 34]. In addition to hypertrophic
gastropathy, hypergastrinemia causes ECL cell hyperplasia in the oxyntic mucosa. ECL
tumors may also occur in addition to ECL cell hyperplasia, but the tumors are thought to
be promoted by the genetic changes underlying MEN-I since similar tumors have never
been observed in association with sporadic ZES [8], apart from one doubtful case [35].
The MEN-1/ZES associated tumors are usually small (mean 0.5 cm; range 0.1-1.6 cm) but
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Table 1. Features ofType 1 GNET.
Relative incidence 51-88 percent
Association with other diseases Chronic atrophic fundus gastritis
Pernicious anemia
Hypergastrinemia Present
Site Gastric body fundus
Precursor lesions Present
Occurrence Multiple
Size < 1 cm (95 percent)
Hormonal syndrome No
Metastasis 3-8 percent nodal
1-4 percent hepatic
Table 2. Features oflype 2 GNET.
Relative incidence 12-18 percent
Association with other diseases No
Hypergastrinemia Absent
Site Gastric body fundus (90 percent)
Gastric antrum (10 percent)
Precursor lesions Absent
Occurrence Solitary (85 percent)
Size > 1 cm (25 percent)
Hormonal syndrome Carcinoid syndrome (7 percent)
ZES (very rare)
Metastasis 26 percent nodal
17 percent hepatic
Table 3: Gastrin-producing GNETs.
Number of
Author patients ZES Site
Royston et al. 1972 [23] 1 Yes Antropyloric
Larsson et al. 1973 [24] 1 Yes Antropyloric
Soule et al. 1976 [25] 1 Yes Antropyloric
Berger et al. 1978 [26] 1 Yes Antropyloric
Russo et al. 1980 [27] 1 No Antral-fundic
Thompson et al. 1985 [28] 1 Yes Antral
Rindi et al. 1993 [8] 1 Yes Antropyloric
Ahlmann et al. 1994 [11] 1 No Antral
Mignon et al. 1986 [29]* 2 Yes Gastric
Norton et al. 1986 [30]* 3 Yes Near pylorus
Vogel et al. 1987 [31]* 1 Yes Lesser curvature
Kaplan et al. 1990 [32]* 1 Yes Antrum
*Tumors without immunocytochemical analysis and detailed descriptions.
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Table 4. Features ofType 3 GNET.
Relative incidence 0-13 percent
Association with other diseases ZES and MEN 1
Hypergastrinemia Absent
Site Gastric body fundus
Precursor lesions Present
Occurrence Multiple
Hormonal syndrome No
Metastasis 20 percent nodal
Table 5. Features ofType 4 GNET.
Relative incidence 1-16 percent
Association with other diseases No
Hypergastrinemia No
Site No predilection
Precursor lesions Absent
Occurrence Solitary
Hormonal syndrome No
Metastasis > 90 percent
may occasionally become large [36] or involve the oxyntic mucosa diffusely [37].
Metastasis to the regional lymph nodes has been observed in a few tumors [8, 36], all of
them large.
Type 4 gastric neuroendocrine tumors
This GNET is characterized by its poor differentiation (Table 5). Histologically, the
tumor is composed of medium-sized, rather than small cells, showing high proliferation
activity. At the time ofdiagnosis, most ofthe tumors are already advanced. Their progno-
sis is therefore poor, with three quarters of the patients dying within one year of diagno-
sis due to extensive metastatic disease [8, 10, 38-42].
CONCLUSION
The GNETs show a broad functional and biological spectrum, which makes a divi-
sion into different types necessary. The classification outlined in this paper considers the
morphology and function ofthe tumors and their association with other diseases. On this
basis four types can be distinguished, each with its own clinical relevance.
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